Search

The Supreme Court decision to overturn Roe v. Wade and the growing onslaught of state laws that criminalize abortion are part of a long history of maintaining White supremacy through reproductive control of Black and socially marginalized lives. As public health continues to recognize structural racism as a public health crisis and advances its measurement, it is imperative to explicate the connection between abortion criminalization and White supremacy. In this essay, we highlight how antiabortion policies uphold White supremacy and offer concrete strategies for addressing abortion criminalization in structural racism measures and public health research and practice. (Am J Public Health. 2022;112(11):1662–1667. https://doi.org/10.2105/AJPH.2022.307014 )

Provision of medication abortion in student health centers (SHC) is safe and effective, but only two states require public SHCs to provide such services. Washington state does not require medication abortion in public SHCs, yet abortion demand is greater and out-of-state patients have increased following the Dobbs decision. Here, we estimate demand for medication abortion and describe barriers to care among Washington public university students. Using publicly available data, we estimated that students at the 11 Washington public universities obtained between 404 and 549 medication abortions annually. Students must travel an average of 16 miles (range:1-78) or 73 minutes via public transit (range:22-284) round trip to the nearest abortion-providing facility. Average wait time for the first available appointment was 10 days (range:4-14), and average cost was $711. Public universities can play an integral role in expanding abortion access post-Dobbs by providing medication abortion, effectively reducing barriers to care for students.

Few studies have characterized bone mineral density (BMD) among health young African women. In our study of 496 Ugandan women age ≤25 years, we found that women had healthy BMD that were lower on average than the standard reference ranges. Reference ranges available for BMD measurements need greater precision.Data describing bone mineral density (BMD), nutrient intake, and body composition among healthy, young women in sub-Saharan Africa are limited. Using baseline data from a cohort of young, healthy Ugandan women, we summarize bone health and associated risk factors for reduced bone mass.Using baseline data from Ugandan women ages 16-25 years who enrolled in an ongoing cohort study of bone health with concurrent use of injectable contraception and oral HIV pre-exposure prophylaxis, we describe the distribution of BMD, nutrient intake, physical activity, and body composition. The association of low BMD (1 or more standard deviations below the age, sex, and race-matched reference range from the USA) and calcium intake, vitamin D intake, physical activity, and body composition was estimated using multivariable logistic regression.In 496 healthy, Ugandan women with median age of 20 years (interquartile range [IQR] 19-21) and median fat:lean mass ratio of 0.55 (IQR 0.46-0.64), median lumbar spine and total hip BMD was 0.9g/cmsup2/sup(IQR 0.9-1.0) each. For lumbar spine, Z-score distributions were lower overall than the reference population and 9.3% and 36.3% of women had Z-scoregt;2 andgt;1 standard deviations below the reference range, respectively. For total hip, Z-scores were similar to the reference population and 1.0% and 12.3% of women had Z-scoregt;2 andgt;1 standard deviations below the reference range, respectively. In the week prior to enrollment, 41.1% of women consumedgt;7 servings of calcium, 56.5% hadgt;7 servings of vitamin D, and 98.6% reported ≥2.5 h of physical activity. Having greater body fat was associated with greater frequency of low lumbar spine BMD (plt;0.01 for fat:lean mass ratio, total body fat percentage, waist circumference, and BMI).Young Ugandan women exhibited healthy levels of BMD that were lower than the reference range population.

Objective To compare medroxyprogesterone acetate (MPA) concentrations between HIV-positive women on antiretroviral therapy (ART) and HIV-negative women initiating depot medroxyprogesterone (DMPA) injectable. Study design Secondary analysis of 28 HIV-positive women on non-nucleoside reverse transcriptase inhibitor-containing ART regimens and 10 HIV-negative women randomized to initiate DMPA in a clinical trial of progestin contraception in Malawi. Results MPA concentrations were significantly lower among HIV-positive women on ART, compared with HIV-negative women, at week 4 and week 13 (p=.03 for both), but not at day 3 or week 26 post-DMPA initiation. Conclusions Antiretroviral medications may affect MPA metabolism in HIV-positive African women.

Introduction Post‐abortion clinics located in regions with high HIV burden may ideal locations to integrate counselling and delivery of HIV pre‐exposure prophylaxis (PrEP), aligning with normative goals for integrated delivery of HIV and reproductive health care. The objective of this study was to gauge the degree to which Kenyan women seeking care for a pregnancy loss, including induced abortion, are at risk for HIV and whether women would welcome an introduction to PrEP prior to discharge from post‐abortion care. Methods We conducted a mixed‐methods study from August 2019 to February 2020 with women ages 15 to 30 recruited sequentially as they were accessing post‐abortion care at public and private facilities in Thika and Kisumu, Kenya. Data collection was through a cross‐sectional survey and laboratory testing for common sexually transmitted infections (N = 200), and in‐depth interviews (N = 30). Descriptive statistics summarize PrEP knowledge and referrals and a multivariable log‐link binomial model estimated correlates of receiving a referral for PrEP. Qualitative data were analysed using inductive and deductive approaches. Results Among 200 HIV‐negative women (median age 21.0, interquartile range 19.0 to 22.0), the prevalence of Chlamydia trachomatis was 18.2% and Neisseria gonorrhoeae was 2.0%. Half of the women scored ≥5 on a validated tool that would correspond to an expected HIV incidence of 9.5% per year. Approximately half (55.8%) of women were familiar with PrEP prior to the study and 33.3% received a referral from study staff to a clinic offering PrEP. In qualitative interviews, women expressed interest in accessing PrEP from the gynaecology ward that provided post‐abortion care but they preferred alternative locations for PrEP refills. Conclusions Kenyan women accessing post‐abortion care have substantial HIV risk and were favourable about the idea of receiving support to initiate PrEP as part of care offered during post‐abortion care. These settings can be integrated into national PrEP programmes as locations providing PrEP referrals and initiation.

Self-report of sexual behaviours in clinical studies is often subject to misreporting due to recall or social desirability bias or misinterpretation of the study questionnaires.1 Use of biomarkers of semen exposure, such as the detection of prostate-specific antigen (PSA) in vaginal secretions, offers an additional means of assessing sexual behaviours and condom use that is not subject to reporting biases.2 In a secondary analysis of a clinical trial of hormonal contraception in Malawi,3 we examined associations of discordance between PSA detection and self-report of condomless sex over time with participant characteristics using log-binomial regression analyses with generalised estimating equations for repeated measures. All analyses were conducted using SAS V.9.3 (SAS Institute, Cary, North Carolina, USA). Testing …

Objectives: Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation. Our secondary objective was to evaluate the pregnancy rate among levonorgestrel implant users on efavirenz. Study design: We performed a subanalysis of 42 Malawian women randomized to initiate the levonorgestrel implant as part of a parent randomized clinical trial. Our subset included 30 HIV-infected women taking efavirenz and 12 HIV-uninfected women not taking efavirenz. They underwent urine pregnancy testing every 3 months and serum levonorgestrel testing at day 3 and months 1, 3, 6, 12, 18, 24, 27 and 30 after implant initiation. Geometric mean levonorgestrel concentrations were calculated for efavirenz users and non-efavirenz users at each time point. Results: The geometric mean levonorgestrel concentrations were lower for efavirenz users than non-efavirenz users at every time point; the geometric mean ratio for efavirenz users:non-efavirenz users ranged from 0.60 [90% confidence interval (CI) 0.46–0.79] at 1 month to 0.27 (90% CI 0.12–0.61) at 30 months after implant insertion. No pregnancies occurred over 60 woman-years of concomitant levonorgestrel implant and efavirenz use, although 11 women had levonorgestrel concentrations

ObjectivesTo assess potentially missed sexually transmitted infections (STIs), we compared clinically diagnosed STIs to laboratory-confirmed diagnoses of gonorrhoea (GC), chlamydia (CT) and trichomonas (Tvag).DesignSecondary analysis of a randomised controlled trial.SettingWe used data and specimens previously collected for the Sino-Implant Study in Kingston, Jamaica.ParticipantsThe Sino-Implant Study randomised 414 women to receive a levonorgestrel implant at either baseline or 3 months post-enrolment to evaluate unprotected sex after implant initiation. This analysis used 254 available vaginal swab samples.Outcome measuresClinically diagnosed STIs were determined from medical records by assessing clinical impressions and prescriptions. Laboratory-confirmed STIs included GC, CT and Tvag tested by Aptima Combo 2 for CT/GC and Aptima Tvag assays (Hologic, San Diego, California, USA). Log-binomial regression models fit with generalised estimating equations were used to estimate associations of clinically diagnosed STIs with laboratory-confirmed diagnoses and demographic and behavioural characteristics.ResultsOverall, 195 (76.8%) women had laboratory-confirmed STI (CT, GC or Tvag) while only 65 (25.6%) women had clinically diagnosed cervicitis and/or vaginitis during the study period. Clinical diagnosis missed 79.7% of laboratory-confirmed STIs: 85% of GC (n=17/20), 78.8% of CT (n=141/179) and 80.0% of Tvag (n=180/225). Hormonal contraceptive use in the month prior to the study visit was significantly associated with clinical diagnosis at any time point (prevalence ratio (PR): 1.65, 95% CI 1.07 to 2.54). As age increased, clinically missed infections significantly decreased (PR: 0.98 per year increase, 95% CI 0.97 to 1.00).ConclusionsThe prevalence of laboratory-confirmed STIs was much higher than what was captured by clinical diagnosis. GC, CT and Tvag were not accurately detected without lab confirmation. Missed diagnoses decreased with older age. Increased laboratory capacity and refinement of the syndromic approach are needed to protect the health of sexually active Jamaican women.Trial registration numberNCT01684358.

Background Circulating melatonin is a good candidate biomarker for studies of circadian rhythms and circadian disruption. However, epidemiologic studies on circulating melatonin are limited because melatonin is secreted at night, yet most epidemiologic studies collect blood during the day when melatonin levels are very low, and assays are lacking that are ultrasensitive to detect low levels of melatonin reliably. Objective To assess the performance of a refined radioimmunoassay in measuring morning melatonin among women. Methods We used morning serum samples from 47 postmenopausal women ages 48–80 years without a history of breast cancer who participated in the San Francisco Bay Area Breast Cancer Study, including 19 women who had duplicate measurements. The coefficient of variation (CV) and intraclass coefficient (ICC) were estimated using the random effect model. Results Reproducibility for the assay was satisfactory, with a CV of 11.2% and an ICC of 98.9%; correlation between the replicate samples was also high (R = 0.96). In the 47 women, serum melatonin levels ranged from 0.6 to 62.6 pg/ml, with a median of 7.0 pg/ml. Conclusion Our results suggest that it is possible to reliably measure melatonin in postmenopausal women in morning serum samples in large epidemiologic studies to evaluate the role of melatonin in cancer etiology or prognosis.

Introduction Vaginal prostate-specific antigen (PSA) is a biomarker of recent semen exposure that may overcome potential fallacies of self-reported sexual behaviours, improving sexual exposure assessment in HIV/STI research. Methods We conducted a cohort study to compare PSA detection and self-reported unprotected sex using data from a clinical trial in Malawi that randomised 73 HIV-infected and 24 HIV-uninfected women to depot medroxyprogesterone acetate injectable or levonorgestrel implant. Women were advised to abstain from vaginal intercourse or use a condom the day preceding study visits. We tested 539 vaginal swabs from 97 women for PSA using the ABAcard p30 rapid strip test (Abacus Diagnostics, Inc., West Hills, CA). Self-reported sexual behaviours and vaginal swabs were collected at six study visits. Log-binomial regression with generalised estimating equations were used to estimate associations of PSA detection and reported unprotected sex with demographic and behavioural factors, adjusting for study arm and pre- vs. post-contraception initiation. Results Overall, 55 (57%) women tested positive for PSA and 54 (56%) women reported unprotected sex. Among PSA-positive samples, 62% (65/105) of instances reported no unprotected sex. The following were associated with PSA detection: HIV-negative status (Prevalence Ratio (PR): 1.69, 95% Confidence Interval (CI):1.09, 2.61), younger age (PR: 1.04, CI: 1.00, 1.08), reported unprotected sex (PR: 2.48, CI: 1.70, 3.60), and sex within past 48 hours (PR: 4.68, CI: 3.00, 7.30). The same factors were significantly associated with self-reported unprotected sex, as was PSA detection (PR: 2.45, CI: 1.7, 3.53). Conclusions Self-reported sexual behaviours were significantly associated with PSA detection. However, PSA was detected among women reporting no unprotected sex, suggesting misreporting of condom use or condom failure. HIV-negative status and younger age were associated with unprotected sex, suggesting more frequent biases in research data for these groups based on social desirability and non-adherence to protocols.